NEW YORK, July 26 – Sensium Technologies has expanded its license to protein biochip technology from the University of Alberta and Canadian technology transfer company PENCE, Sensium said Thursday.

Sensium, the proteomics subsidiary of Aurora, Ontario-based biopharmaceutical company Helix BioPharma, will now be able to use the technology exclusively in drug discovery, as well as in other applications. The original license dates from 1996.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.